Leonard Wossnig

Leonard is Co-Founder and CTO at Forgent AI, a company building AI Agents for public procurement. Alongside his industry role, he is an active academic contributor through his role as an Honorary Research Fellow in Computer Science at University College London and a startup advisor and board member.

He previously served as Chief Technology Officer at LabGenius, a London based biotech company that develops next-generation therapeutic antibodies using a combination of robotic automation, synthetic biology, and advanced machine learning to run full design-build-test-learn cycles. As CTO he was leading a team of Data Scientists (including Bioinformaticians and Machine Learning Engineers), Software Engineers, and Robotic Automation Experts to develop and further enhance LabGenius’ data-driven platform capabilities. 

Prior to LabGenius, Leonard was VP of AI at Odyssey Therapeutics, where he led a team of machine learning experts and software engineers to develop a machine learning platform for generative design and proprety prediction in the areas of cancer and inflammation. Odyssey raised more than $750M in capital and was one of the fastest growing U.S. Biotechs in 2022 backed by Orbimed and General Catalyst among others.

In 2018, Leonard co-founded Rahko, a machine learning SaaS company focussing on generative AI and machine learning models for small data sets. Rahko software was successfully applied to many applications including generative molecular design and small molecule property prediction. The company based backed by Balderton Capital and had contracts with several major Pharma companies before it was ultimately sold to Odyssey Therapeutics in 2021. Leonard led the company as CEO from the inception until its acquisition. 

Leonard holds a PhD from University College London where he was a Google PhD fellow in Computer Science and published more than a dozen articles and patents including several in high profile journals.